IDEXX Laboratories, Inc. (IDXX) Holdings Increased by Quantbot Technologies LP

Quantbot Technologies LP raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 229.6% in the third quarter, according to its most recent filing with the SEC. The firm owned 36,034 shares of the company’s stock after purchasing an additional 25,102 shares during the quarter. IDEXX Laboratories makes up approximately 0.5% of Quantbot Technologies LP’s investment portfolio, making the stock its 28th largest holding. Quantbot Technologies LP’s holdings in IDEXX Laboratories were worth $5,602,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in IDEXX Laboratories by 4.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,264,579 shares of the company’s stock valued at $1,495,488,000 after purchasing an additional 354,024 shares during the period. BlackRock Inc. increased its position in IDEXX Laboratories by 10.5% during the 2nd quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock valued at $1,146,142,000 after purchasing an additional 673,347 shares during the period. Koch Industries Inc. increased its position in IDEXX Laboratories by 44,533.1% during the 2nd quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock valued at $1,391,000 after purchasing an additional 1,396,113 shares during the period. Renaissance Technologies LLC increased its position in IDEXX Laboratories by 38.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,351,900 shares of the company’s stock valued at $218,224,000 after purchasing an additional 376,300 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its position in IDEXX Laboratories by 42.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock valued at $211,567,000 after purchasing an additional 392,790 shares during the period. 88.03% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “IDEXX Laboratories, Inc. (IDXX) Holdings Increased by Quantbot Technologies LP” was first published by Markets Daily and is owned by of Markets Daily. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.themarketsdaily.com/2017/11/16/idexx-laboratories-inc-idxx-holdings-increased-by-quantbot-technologies-lp.html.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded up $2.43 during trading on Thursday, hitting $153.83. The company’s stock had a trading volume of 286,217 shares, compared to its average volume of 529,013. The company has a market cap of $13,420.00, a PE ratio of 50.35, a price-to-earnings-growth ratio of 2.26 and a beta of 0.46. IDEXX Laboratories, Inc. has a 52-week low of $112.41 and a 52-week high of $173.01. The company has a debt-to-equity ratio of -12.48, a current ratio of 0.95 and a quick ratio of 0.77.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.05. The business had revenue of $492.00 million for the quarter, compared to the consensus estimate of $492.94 million. During the same quarter in the previous year, the company posted $0.62 earnings per share. IDEXX Laboratories’s quarterly revenue was up 9.7% on a year-over-year basis. sell-side analysts expect that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current fiscal year.

A number of research firms have weighed in on IDXX. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 target price for the company in a research report on Tuesday, October 24th. Stifel Nicolaus restated a “buy” rating and set a $185.00 price target on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Canaccord Genuity restated a “buy” rating and set a $180.00 price target on shares of IDEXX Laboratories in a report on Friday, October 6th. Bank of America Corporation upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target on the stock in a report on Wednesday, August 23rd. Finally, BidaskClub cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. IDEXX Laboratories has a consensus rating of “Hold” and an average target price of $173.67.

In related news, Chairman Jonathan W. Ayers sold 13,000 shares of the stock in a transaction on Monday, August 28th. The stock was sold at an average price of $150.79, for a total value of $1,960,270.00. Following the transaction, the chairman now directly owns 1,044,034 shares in the company, valued at approximately $157,429,886.86. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Rebecca M. Henderson sold 2,578 shares of the stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $152.86, for a total value of $394,073.08. Following the completion of the transaction, the director now owns 17,274 shares in the company, valued at $2,640,503.64. The disclosure for this sale can be found here. Over the last quarter, insiders sold 92,734 shares of company stock worth $14,083,486. 2.77% of the stock is owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply